CoChat

Age‐related changes in testosterone and the role of replacement therapy in older men

Allan, Carolyn A., McLachlan, Robert I. · 2004 · Clinical Endocrinology
Cited by 128

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Western populations represent an ageing society with continuing gains being made in life expectancy; a male born in Australia has a healthy life expectancy of 70 years with slightly lower expectations for those born in the UK and USA (WHO, 2001). The search for ways to maintain and enhance physical health and well-being is endless. Rather than aiming to simply live longer, people aspire to undertake 'active ageing' (WHO, 2002), with an emphasis on quality of life. Attention has been focussed on the possibility that testosterone replacement therapy may be beneficial to the quality of life of men in middle age and beyond, akin to that of the role of oestrogen replacement for symptomatic peri- and postmenopausal women (Hlatky et al., 2002). Although the clinical presentation of androgen deficiency in men with primary or secondary testicular failure is well recognized and the benefits of treatment well established (Allan & McLachlan, 2003), whether testosterone replacement therapy is beneficial for older men with more subtle age-associated declines in serum testosterone levels is beneficial remains uncertain. Ill-defined terms such as 'andropause' or 'partial androgen deficiency of ageing men' have been popularized and underscore the increasing use of testosterone treatment for a range of ailments prevalent in older men. In the USA, the market for testosterone therapies has increased from US$49 million to almost US$400 million between 1997 and , with the majority of prescribing being for men 40 years and older. No matter how well-intentioned, such treatment cannot escape evaluation according to the modern principles of evidence-based medicine. Recent experiences in the field of female HRT (Hulley et al., 1998; Rossouw et al., 2002) serve to remind us of the need for properly designed and powered randomized, placebo-controlled data, and for caution in extrapolating cross-sectional or surrogate end-point data. We will discuss the extent of age-related decline in testosterone and the confounding effects of concomitant illness, the physiology of the changes in the hypothalamo–pituitary–testicular (HPT) axis, and the approaches to the laboratory assessment of hypoandrogenism in older men. The effects of androgens on key target tissues and the existing data from the limited number of placebo-controlled trials regarding the benefits and potential risks of its usage will be discussed. Unlike the predictable 90% fall in serum oestradiol across the menopause (Burger et al., 2002), testosterone levels in men begin to decline in the late third or early fourth decade and diminish at a constant rate thereafter (Baker et al., 1976b; Leifke et al., 2000; Harman et al., 2001). Many cross-sectional and several longitudinal studies have now documented significantly lower total testosterone levels in older men when compared to their younger counterparts (Feldman et al., 2002; Zumoff et al., 1982; Gray et al., 1991a, 1991b; Tenover & Bremner, 1991; Simon et al., 1992; Morley et al., 1997; Zmuda et al., 1997; Ferrini & Barrett-Connor, 1998; Harman et al., 2001). Those studies that have failed to identify this fall in testosterone have been criticized for the timing of sample collection (Harman & Tsitouras, 1980), the small numbers of subjects (Nankin & Calkins, 1986), or because of unexpectedly low testosterone levels in the younger subjects (Sparrow et al., 1980; Nieschlag et al., 1982). The absolute rate of decline in total testosterone levels in longitudinal studies varies threefold – from 0·11 nm (Harman et al., 2001) to 0·29 nm (Feldman et al., 2002) to 0·38 nm (Morley et al., 1997) per year. As a percentage of baseline values, cross-sectional studies estimate the rate of decline to be 0·5–0·8% per year (Davidson et al., 1983; Gray et al., 1991b; Simon et al., 1992), while longitudinal studies suggest a greater rate of decline, e.g. 1·6% per annum in the Massachusetts Male Ageing Study (MMAS; Feldman et al., 2002). Concomitant with the fall in total testosterone is a rise in SHBG levels with ageing (Field et al., 1994; Harman et al., 2001), estimated to be 1·3% per year in a cohort aged 40 years and over (Feldman et al., 2002). As a result of the combined effects of a rise in SHBG and a fall in total testosterone, calculated free testosterone levels decrease by approximately 2–3% per year (Feldman et al., 2002). The relationship between the changes in total testosterone and SHBG is unclear. Excluding obese men, in whom SHBG levels are reduced as a function of adiposity (Field et al., 1994), one group has described a fall in total testosterone from the age of 30 years with SHBG levels rising only from the age of 50 years (Leifke et al., 2000), whereas others have identified an earlier rise in SHBG with total testosterone levels falling only from the age of 55 years (Vermeulen et al., 1996). Ageing and obesity have opposing effects on SHBG levels. Given the increasing prevalence of obesity (Ball et al., 2002; 65% of Australian me

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2004.02002.x

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 128

Metadata

Authors
Allan, C. A., & McLachlan, R. I.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2004-04-08
Volume
60
Issue
6
Pages
653-670
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1981476069
Cited by
128
References
55
FWCI
3.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Age‐related changes in testosterone and the role of replacement therapy in older men. https://app.cochat.ai/papers/10.1111/j.1365-2265.2004.02002.x
The paper
Allan, C. A., & McLachlan, R. I. (2004). Age‐related changes in testosterone and the role of replacement therapy in older men. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2004.02002.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.